- Click on the title of each paper to access MedLine abstract at NLM site
Colorectal Cancer - Adjuvant Therapy

                                                          <return>

Hochster HS. Bevacizumab in combination with chemotherapy: first-line treatment of patients with metastatic colorectal cancer.
Semin Oncol. 2006 Oct;33(5 Suppl 10):S8-S14.  

Norum J. Cetuximab in the treatment of metastatic colorectal cancer: a model-based cost-effectiveness analysis. J Chemother. 2006 Oct;18(5):532-7.   

Warusavitarne J, Schnitzler M. The role of chemotherapy in microsatellite unstable (MSI-H) colorectal cancer. Int J Colorectal Dis. 2006 Nov 16;

D'Angelica M, Kornprat P, Gonen M, Chung KY, Jarnagin WR, Dematteo RP, Fong Y, Kemeny N, Blumgart LH, Saltz LB. Lack of Evidence for Increased Operative Morbidity After Hepatectomy with Perioperative Use of Bevacizumab: A Matched Case-Control Study. Ann Surg Oncol. 2006 Nov 11;

Prosnitz RG, Patwardhan MB, Samsa GP, Mantyh CR, Fisher DA, McCrory DC, Cline KE, Gray RN, Morse MA.  Quality measures for the use of adjuvant chemotherapy and radiation therapy in patients with colorectal cancer: a systematic review.
Cancer. 2006 Nov 15;107(10):2352-60.

Eggington S, Tappenden P, Pandor A, Paisley S, Saunders M, Seymour M, Sutcliffe P, Chilcott J. Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer. Br J Cancer. 2006 Nov 6;95(9):1195-201.

Benoist S, Brouquet A, Penna C, Julie C, El Hajjam M, Chagnon S, Mitry E, Rougier P, Nordlinger B. Complete response of colorectal liver metastases after chemotherapy: does it mean cure?
J Clin Oncol. 2006 Aug 20;24(24):3939-45.

Chung KY, Kelsen D. Adjuvant Therapy for Stage II Colorectal Cancer: Who and with What? Curr Treat Options Gastroenterol. 2006 Jun;9(3):272-80.

Oki E, Kakeji Y, Yoshida R, Ikeda K, Nishida K, Koga T, Egashira A, Tokunaga E, Morita M, Baba H, Maehara Y. [A randomized controlled trial to evaluate the effect of adjuvant oral fluoropyrimidine derivative therapy after curative resection for stage II/III rectal cancer-adjuvant chemotherapy trial of S-1 for rectal cancer (ACTS-RC):] Gan To Kagaku Ryoho. 2006 Jun;33 Suppl 1:138-43. Japanese

Yoshimatsu K, Umehara A, Ishibashi K, Yokomizo H, Yoshida K, Fujimoto T, Watanabe K, Ogawa K. Indication and efficacy of adjuvant chemotherapy with oral fluoropyrimidines for dukes' B colorectal cancer. Anticancer Res. 2006 Jul-Aug;26(4B):3089-93.

Capirci C, Rubello D, Chierichetti F, Crepaldi G, Fanti S, Mandoliti G, Salviato S, Boni G, Rampin L, Polico C, Mariani G.  Long-term prognostic value of 18F-FDG PET in patients with locally advanced rectal cancer previously treated with neoadjuvant radiochemotherapy. AJR Am J Roentgenol. 2006 Aug;187(2):W202-8.

Knutsen A, Adell G, Sun XF. Inflammatory infiltration, fibrosis, necrosis and mucinous content in relation to clinicopathological and molecular factors in rectal cancers with or without preoperative radiotherapy. Oncol Rep. 2006 Aug;16(2):321-7.

Ward SE, Kaltenthaler E, Cowan J, Marples M, Orr B, Seymour MT. The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer. Br J Cancer. 2006 Jul 3;95(1):27-34.

Pelz JO, Doerfer J, Dimmler A, Hohenberger W, Meyer T. Histological response of peritoneal carcinomatosis after hyperthermic intraperitoneal chemoperfusion (HIPEC) in experimental investigations. BMC Cancer. 2006 Jun 22;6:162.

Sobrero A. Should adjuvant chemotherapy become standard treatment for patients with stage II colon cancer? For the proposal. Lancet Oncol. 2006 Jun;7(6):515-6.

Roels S, Duthoy W, Haustermans K, Penninckx F, Vandecaveye V,  Boterberg T, De Neve W. Definition and delineation of the clinical target volume for rectal cancer.  Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):1129-42.

Crozier JE, McKee RF, McArdle CS, Angerson WJ, Anderson JH, Horgan PG, McMillan DC. The presence of a systemic inflammatory response predicts poorer survival in patients receiving adjuvant 5-FU chemotherapy following potentially curative resection for colorectal cancer. Br J Cancer. 2006 Jun 19;94(12):1833-6.

Vulto AJ, Lemmens VE, Louwman MW, Janssen-Heijnen ML, Poortmans PH, Lybeert ML, Coebergh JW. The influence of age and comorbidity on receiving radiotherapy as part of primary treatment for cancer in South Netherlands, 1995 to 2002. Cancer. 2006 Jun 15;106(12):2734-42.

Burton S, Brown G, Daniels I, Norman A, Swift I, Abulafi M, Wotherspoon A, Tait D. MRI identified prognostic features of tumors in distal sigmoid, rectosigmoid, and upper rectum: treatment with radiotherapy and chemotherapy.
Int J Radiat Oncol Biol Phys. 2006 Jun 1;65(2):445-51.

Goto A, Yamada Y, Yasui H, Kato K, Hamaguchi T, Muro K, Shimada Y, Shirao K. Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer. Ann Oncol. 2006 Jun;17(6):968-73.

Bakx R, Emous M, Legemate DA, Zoetmulder FA, van Tienhoven G, Bemelman WA, van Lanschot JJ. Harm and benefits of short-term pre-operative radiotherapy in patients with resectable rectal carcinomas. Eur J Surg Oncol. 2006 Jun;32(5):520-6.

Melichar B, Voboril Z, Cerman J Jr, Melicharova K, Mergancova J, Voboril R, Jandik P. Survival of patients with colorectal cancer liver metastases treated by regional chemotherapy.
Hepatogastroenterology. 2006 May-Jun;53(69):426-34.

Assenat E, Duffour J, Ychou M.  [Irinotecan for the treatment of metastatic colorectal cancer] Bull Cancer. 2006 May 1;93(5):507-15. Review. French.

Zheng H, Chen JZ, Liao WJ, Luo RC.  [Efficacy of Avastin in combination with irinotecan for metastatic colorectal cancer]
Nan Fang Yi Ke Da Xue Xue Bao. 2006 May;26(5):689-91. Chinese.

Crozier JE, McKee RF, McArdle CS, Angerson WJ, Anderson JH, Horgan PG, McMillan DC. The presence of a systemic inflammatory response predicts poorer survival in patients receiving adjuvant 5-FU chemotherapy following potentially curative resection for colorectal cancer. Br J Cancer. 2006 Jun 19;94(12):1833-6.

Hu JB, Sun XN, Yang QC, Xu J, Wang Q, He C. Three-dimensional conformal radiotherapy combined with FOLFOX4 chemotherapy for unresectable recurrent rectal cancer. World J Gastroenterol. 2006 Apr 28;12(16):2610-4.

Sturm I, Rau B, Schlag PM, Wust P, Hildebrandt B, Riess H, Hauptmann S, Dorken B, Daniel PT. Genetic dissection of apoptosis and cell cycle control in response of colorectal cancer treated with preoperative radiochemotherapy.
BMC Cancer. 2006 May 10;6(1):124

Neugut AI, Matasar M, Wang X, McBride R, Jacobson JS, Tsai WY, Grann VR, Hershman DL.  Duration of adjuvant chemotherapy for colon cancer and survival among the elderly.
J Clin Oncol. 2006 May 20;24(15):2368-75.

Hasegawa S, Mukai M, Sato S, Ninomiya H, Wakui K, Komatsu N, Tajima T, Nakasaki H, Makuuchi H. Long-term survival and tumor 5-FU sensitivity in patients with stage IV colorectal cancer and peritoneal dissemination. Oncol Rep. 2006 May;15(5):1185-90.

Feliu J, Salud A, Escudero P, Lopez-Gomez L, Bolanos M, Galan A, Vicent JM, Yubero A, Losa F, De Castro J, de Mon MA, Casado E, Gonzalez-Baron M. XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. Br J Cancer. 2006 Apr 10;94(7):969-75.

Souglakos J, Androulakis N, Syrigos K, Polyzos A, Ziras N, Athanasiadis A, Kakolyris S, Tsousis S, Kouroussis Ch, Vamvakas L, Kalykaki A, Samonis G, Mavroudis D, Georgoulias V. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer. 2006 Mar 27;94(6):798-805.

Kemeny NE, Niedzwiecki D, Hollis DR, Lenz HJ, Warren RS, Naughton MJ, Weeks JC, Sigurdson ER, Herndon JE 2nd, Zhang C, Mayer RJ. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481).
J Clin Oncol. 2006 Mar 20;24(9):1395-403.

Ortholan C, Francois E, Thomas O, Benchimol D, Baulieux J, Bosset JF, Gerard JP. Role of radiotherapy with surgery for T3 and resectable T4 rectal cancer: evidence from randomized trials.
Dis Colon Rectum. 2006 Mar;49(3):302-10.

Homsi J, Garrett CR. Hepatic arterial infusion of chemotherapy for hepatic metastases from colorectal cancer. Cancer Control. 2006 Jan-Feb;13(1):42-7.

Vincenzi B, Santini D, Russo A, Silletta M, Gavasci M, Battistoni F, Di Cuonzo G, Rocci L, Gebbia N, Tonini G. Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients.
Ann Oncol. 2006 Feb 28; 

Kemeny NE, Niedzwiecki D, Hollis DR, Lenz HJ, Warren RS, Naughton MJ, Weeks JC, Sigurdson ER, Herndon JE 2nd, Zhang C, Mayer RJ. Hepatic Arterial Infusion Versus Systemic Therapy for Hepatic Metastases From Colorectal Cancer: A Randomized Trial of Efficacy, Quality of Life, and Molecular Markers (CALGB 9481).
J Clin Oncol. 2006 Mar 20;24(9):1395-403.  

Correale P, Cusi MG, Micheli L, Nencini C, Del Vecchio MT, Torino F, Aquino A, Bonmassar E, Francini G, Giorgi G.  Chemo-immunotherapy of colorectal carcinoma: preclinical rationale and clinical experience. Invest New Drugs. 2006 Feb 24;  

Andre T, Tournigand C, Achille E, Tubiana-Mathieu N, Lledo G, Raoul Y, Carola E, Flesch M, Muron T, Boutan-Laroze A, Guerin Meyer V, Boaziz C, Maigre M, Ganem G, Mousseau M, Mounedji-Boudiaf L, de Gramont A.  [Adjuvant treatment of colon cancer MOSAIC study's main results Bull Cancer. 2006 Feb 1;93 Suppl 1:S5-9. French. 

de Kort SJ, Willemse PH, Habraken JM, de Haes HC, Willems DL, Richel DJ. Quality of life versus prolongation of life in patients treated with chemotherapy in advanced colorectal cancer: A review of randomized controlled clinical trials. Eur J Cancer. 2006 Feb 13; 

Glynne-Jones R, Grainger J, Harrison M, Ostler P, Makris A. Neoadjuvant chemotherapy prior to preoperative chemoradiation or radiation in rectal cancer: should we be more cautious?
Br J Cancer. 2006 Feb 13;94(3):363-71.  

Jensen SA, Lonborg JT, Sorensen JB. Benefits and risks of palliative capecitabine based therapy to elderly patients with advanced colorectal cancer: Danish single centre experiences.
Acta Oncol. 2006;45(1):67-76. 

Park YA, Sohn SK, Seong J, Baik SH, Lee KY, Kim NK, Cho CW. Serum CEA as a predictor for the response to preoperative chemoradiation in rectal cancer. J Surg Oncol. 2006 Feb 1;93(2):145-50. 

Konski A, Hoffman J, Sigurdson E, Haluszka O, Engstrom P, Cheng JD, Cohen SJ, Watson JC, Eisenberg D, McGarrity E, Freedman G, Meropol NJ. Can molecular imaging predict response to preoperative chemoradiation in patients with rectal cancer? A Fox Chase Cancer Center prospective experience. Semin Oncol. 2005 Dec;32(6 Suppl 9):S63-7. 

Marshall J. The role of bevacizumab as first-line therapy for colon cancer. Semin Oncol. 2005 Dec;32(6 Suppl 9):S43-7. Review.  

Masi G, Cupini S, Marcucci L, Cerri E, Loupakis F, Allegrini G, Brunetti IM, Pfanner E, Viti M, Goletti O, Filipponi F, Falcone A. Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer.
Ann Surg Oncol. 2006 Jan;13(1):58-65.  

Toyokawa A, Tsujimura T, Hamabe Y, Sato S, Mukubou H, Wakahara T, Kaji M, Tsukamoto T, Wakita K, Onishi N, Ishida T, Watanabe A, Fujiwara H, Mukai H.  [Clinical study of ambulatory patient cancer chemotherapy for advanced colorectal cancer]
Gan To Kagaku Ryoho. 2005 Dec;32(13):2087-90. Japanese.  

Popov I, Jelic S, Krivokapic Z, Micev M, Babic D, Zdrale Z. What is the best sequence of chemotherapy in advanced colorectal cancer? Final results of a five-arm study. Chemotherapy. 2006;52(1):20-2. 

Duff SE, Jeziorska M, Rosa DD, Kumar S, Haboubi N, Sherlock D, O'Dwyer ST, Jayson GC. Vascular endothelial growth factors and receptors in colorectal cancer: implications for anti-angiogenic therapy. Eur J Cancer. 2006 Jan;42(1):112-7.  

Birgisson H, Pahlman L, Gunnarsson U, Glimelius B; Swedish Rectal Cancer Trial Group. Adverse effects of preoperative radiation therapy for rectal cancer: long-term follow-up of the Swedish Rectal Cancer Trial. J Clin Oncol. 2005 Dec 1;23(34):8697-705. 

Haller DG, Catalano PJ, Macdonald JS, O'Rourke MA, Frontiera MS, Jackson DV, Mayer RJ. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol. 2005 Dec 1;23(34):8671-8. 

Lim JF, Tjandra JJ, Hiscock R, Chao MW, Gibbs P. Preoperative chemoradiation for rectal cancer causes prolonged pudendal nerve terminal motor latency. Dis Colon Rectum. 2006 Jan;49(1):12-9. 

Sargent DJ, Wieand HS, Haller DG, Gray R, Benedetti JK, Buyse M, Labianca R, Seitz JF, O'Callaghan CJ, Francini G, Grothey A, O'Connell M, Catalano PJ, Blanke CD, Kerr D, Green E, Wolmark N, Andre T, Goldberg RM, De Gramont A. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2005 Dec 1;23(34):8664-70.  

Lezoche E, Guerrieri M, Paganini AM, Baldarelli M, De Sanctis A, Lezoche G. Long-term results in patients with T2-3 N0 distal rectal cancer undergoing radiotherapy before transanal endoscopic microsurgery. Br J Surg. 2005 Dec;92(12):1546-52.  

Rodel C, Martus P, Papadoupolos T, Fuzesi L, Klimpfinger M, Fietkau R, Liersch T, Hohenberger W, Raab R, Sauer R, Wittekind C. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol. 2005 Dec 1;23(34):8688-96. 

Zlobec I, Steele R, Compton CC. VEGF as a predictive marker of rectal tumor response to preoperative radiotherapy. Cancer. 2005 Dec 1;104(11):2517-21.   

Chapet O, Gerard JP, Riche B, Alessio A, Mornex F, Romestaing P. Prognostic value of tumor regression evaluated after first course of radiotherapy for anal canal cancer. Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1316-24. 

Bloemendaal AL, Verwaal VJ, van Ruth S, Boot H, Zoetmulder FA. Conventional surgery and systemic chemotherapy for peritoneal carcinomatosis of colorectal origin: a prospective study.
Eur J Surg Oncol. 2005 Dec;31(10):1145-51.

Melichar B, Kohlova T, Vesely P. Survival after oxaliplatin therapy of irinotecan-pretreated advanced colorectal cancer patients.
Hepatogastroenterology. 2005 Nov-Dec;52(66):1707-14.  

Kabashima A, Sakaguchi Y, Okita K, Yamamura S, Ojima Y, Nishizaki T, Tashiro H, Matsuzaka T. [Efficacy of tegafur/uracil plus oral leucovorin therapy for advanced or recurrent colorectal cancer] Gan To Kagaku Ryoho. 2005 Nov;32(12):1935-8. Japanese.  

Sebag-Montefiore D, Glynne-Jones R, Falk S, Meadows HM, Maughan T. A phase I/II study of oxaliplatin when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group (CCOG) study. Br J Cancer. 2005 Oct 31;93(9):993-8.  

Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhil SR, Levitt R, Rowland K, Nair S, Sargent DJ, Donohue JH.Oxaliplatin, Fluorouracil, and Leucovorin for Patients With Unresectable Liver-Only Metastases From Colorectal Cancer: A North Central Cancer Treatment Group Phase II Study.J Clin Oncol. 2005 Oct 17; 

Nogue M, Salud A, Batiste-Alentorn E, Saigi E, Losa F, Cirera L, Mendez M, Campos JM, Galan A, Escudero P, Arcusa A, Manzano H, de Mendizabal EV, de Olaguer JP, Boleda M, Guasch I, Vicente P. Randomised study of tegafur and oral leucovorin versus intravenous 5-fluorouracil and leucovorin in patients with advanced colorectal cancer. Eur J Cancer. 2005 Oct;41(15):2241-9.  

Mukai M, Sato S, Ninomiya H, Wakui K, Komatsu N, Tsuchiya K, Nakasaki H, Makuuchi H. Recurrence and 5-FU sensitivity of stage II/Dukes' B colorectal cancer with occult neoplastic cells in lymph node sinuses. Oncol Rep. 2005 Nov;14(5):1171-6.  

Mukai M, Sato S, Ninomiya H, Wakui K, Komatsu N, Tsuchiya K, Nakasaki H, Makuuchi H. Recurrence and 5-FU sensitivity of stage III/Dukes' C colorectal cancer with occult neoplastic cells in lymph node sinuses. Oncol Rep. 2005 Nov;14(5):1165-9.  

Pachkoria K, Zhang H, Adell G, Jarlsfelt I, Sun XF. Significance of Cox-2 expression in rectal cancers with or without preoperative radiotherapy. Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):739-44.

Schuell B, Gruenberger T, Kornek GV, Dworan N, Depisch D, Lang F, Schneeweiss B, Scheithauer W. Side effects during chemotherapy predict tumour response in advanced colorectal cancer. Br J Cancer. 2005 Oct 3;93(7):744-8.  

Scappaticci FA, Fehrenbacher L, Cartwright T, Hainsworth JD, Heim W, Berlin J, Kabbinavar F, Novotny W, Sarkar S, Hurwitz H. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol. 2005 Sep 1;91(3):173-80.

Wong SF. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
Clin Ther. 2005 Jun;27(6):684-94.  

Saif MW.  Capecitabine versus continuous-infusion 5-Fluorouracil for colorectal cancer: a retrospective efficacy and safety comparison. Clin Colorectal Cancer. 2005 Jul;5(2):89-100.  

Link KH, Kornmann M, Staib L, Redenbacher M, Kron M, Beger HG; Study Group Oncology of Gastrointestinal Tumors. Increase of survival benefit in advanced resectable colon cancer by extent of adjuvant treatment: results of a randomized trial comparing modulation of 5-FU + levamisole with folinic acid or with interferon-alpha. Ann Surg. 2005 Aug;242(2):178-87.  

Mulcahy MF, Benson AB 3rd. Bevacizumab in the treatment of colorectal cancer. Expert Opin Biol Ther. 2005 Jul;5(7):997-1005.  

Shimizu D, Ishikawa T, Ichikawa Y, Togo S, Hayasizaki Y, Okazaki Y, Danenberg PV, Shimada H. Prediction of chemosensitivity of colorectal cancer to 5-fluorouracil by gene expression profiling with cDNA microarrays. Int J Oncol. 2005 Aug;27(2):371-6.  

Ducreux M, Ychou M, Laplanche A, Gamelin E, Lasser P, Husseini F, Quenet F, Viret F, Jacob JH, Boige V, Elias D, Delperro JR, Luboinski M; gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol. 2005 Aug 1;23(22):4881-7.  

Kurt M, Ozkan L, Ercan I, Kahraman S, Zorluoglu A, Gurel S, Memik F, Engin K. Preoperative chemoradiotherapy in patients with locally advanced rectal cancer. Hepatogastroenterology. 2005 Jul-Aug;52(64):1095-100. 

Nordlinger B, Rougier P, Arnaud JP, Debois M, Wils J, Ollier JC, Grobost O, Lasser P, Wals J, Lacourt J, Seitz JF, Guimares dos Santos J, Bleiberg H, Mackiewickz R, Conroy T, Bouche O, Morin T, Baila L, van Cutsem E, Bedenne L. Adjuvant regional chemotherapy and systemic chemotherapy versus systemic chemotherapy alone in patients with stage II-III colorectal cancer: a multicentre randomised controlled phase III trial. Lancet Oncol. 2005 Jul;6(7):459-68.  

Twelves C, Wong A, Nowacki MP, Abt M, Burris H 3rd, Carrato A, Cassidy J, Cervantes A, Fagerberg J, Georgoulias V, Husseini F, Jodrell D, Koralewski P, Kroning H, Maroun J, Marschner N, McKendrick J, Pawlicki M, Rosso R, Schuller J, Seitz JF, Stabuc B, Tujakowski J, Van Hazel G, Zaluski J, Scheithauer W. Capecitabine as adjuvant treatment for stage III colon cancer.
N Engl J Med. 2005 Jun 30;352(26):2696-704.  

Ryan R, Gibbons D, Hyland JM, Treanor D, White A, Mulcahy HE, O'Donoghue DP, Moriarty M, Fennelly D, Sheahan K. Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology. 2005 Aug;47(2):141-6.  

Sadahiro S, Mitomi T, Noto T, Kumada K, Hiki Y, Yamakawa T, Amano T, Oki S, Otani Y, Oka H, Takahashi T, Takemiya S, Nishiyama K, Yamamura T, Tsuchiya S, Ogawa N; Study Group on Postoperative Adjuvant Chemotherapy in Kanagawa Prefecture. [Multicenter comparative study of the recurrence-inhibitory effect of oral fluoropyrimidine drugs in patients with colorectal cancer following curative resection] Gan To Kagaku Ryoho. 2005 Jul;32(7):997-1005. 

McKendrick J, Coutsouvelis J.  Capecitabine: effective oral fluoropyrimidine chemotherapy. Expert Opin Pharmacother. 2005 Jul;6(7):1231-9. 

Vecchio FM, Valentini V, Minsky BD, Padula GD, Venkatraman ES, Balducci M, Micciche F, Ricci R, Morganti AG, Gambacorta MA, Maurizi F, Coco C. The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer. Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):752-60.  

Chessin DB, Enker W, Cohen AM, Paty PB, Weiser MR, Saltz L, Minsky BD, Wong WD, Guillem JG. Complications after preoperative combined modality therapy and radical resection of locally advanced rectal cancer: a 14-year experience from a specialty service. J Am Coll Surg. 2005 Jun;200(6):876-82; discussion 882-4. 

Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol. 2005 Jun 1;23(16):3706-12. 

Negri FV, Wotherspoon A, Cunningham D, Norman AR, Chong G, Ross PJ. Mucinous histology predicts for reduced fluorouracil responsiveness and survival in advanced colorectal cancer.
Ann Oncol. 2005 Aug;16(8):1305-10.  

Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, Mass R, Perrou B, Nelson B, Novotny WF. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol. 2005 Jun 1;23(16):3697-705.

Amichetti M, Lay G, Dessi M, Orru S, Farigu R, Orru P, Farci D, Melis S; Cagliari Neuro-Oncology Group. Results of whole brain radiation therapy in patients with brain metastases from colorectal carcinoma. Tumori. 2005 Mar-pr;91(2):163-7.   

Hurwitz HI, Fehrenbacher L, Hainsworth JD, Heim W, Berlin J, Holmgren E, Hambleton J, Novotny WF, Kabbinavar F. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol. 2005 May 20;23(15):3502-8.  

Motl S. Bevacizumab in combination chemotherapy for colorectal and other cancers. Am J Health Syst Pharm. 2005 May 15;62(10):1021-32. 

Fernandez-Cebrian JM, Vorwald Kuborn P, Pardo de Lama M, Sanjuanbenito Dehesa A, Nevado Santos M, Pacheco Martinez PA, Fernandez-Escudero B.  [Current status of the prognostic value of molecular markers in patients with colorectal cancer and the prediction of response to adjuvant therapy] Clin Transl Oncol. 2005 Apr;7(3):101-9. 

Aschele C, Friso ML, Pucciarelli S, Lonardi S, Sartor L, Fabris G, Urso ED, Del Bianco P, Sotti G, Lise M, Monfardini S. A phase I-II study of weekly oxaliplatin, 5-fluorouracil continuous infusion and preoperative radiotherapy in locally advanced rectal cancer. Ann Oncol. 2005 May 13;  

Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol. 2005 Jun 1;23(16):3706-12 

Feliu J, Escudero P, Llosa F, Bolanos M, Vicent JM, Yubero A, Sanz-Lacalle JJ, Lopez R, Lopez-Gomez L, Casado E, Gomez-Reina MJ, Gonzalez-Baron M. Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an oncopaz cooperative group study. J Clin Oncol. 2005 May 1;23(13):3104-11.   

Negri FV, Wotherspoon A, Cunningham D, Norman AR, Chong G, Ross PJ. Mucinous histology predicts for reduced fluorouracil responsiveness and survival in advanced colorectal cancer. Ann Oncol. 2005 Apr 27; [ 

Schippinger W, Jagoditsch M, Sorre C, Gnant M, Steger G, Hausmaninger H, Mlineritsch B, Schaberl-Moser R, Mischinger HJ, Hofbauer F, Holzberger P, Mittlbock M, Jakesz R; Austrian Breast and Colorectal Cancer Study Group. A prospective randomised trial to study the role of levamisole and interferon alfa in an adjuvant therapy with 5-FU for stage III colon cancer. Br J Cancer. 2005 May 9;92(9):1655-62.  

Lima AP, del Giglio A.  Randomized crossover trial of intravenous 5-FU versus oral UFT both modulated by leucovorin: a one-centre experience. Eur J Cancer Care (Engl). 2005 May;14(2):151-4.  

Diaz-Gonzalez JA, Calvo FA, Cortes J, de La Mata D, Gomez-Espi M, Lozano MA, Lozano E, Serrano J, Herranz R. Preoperative chemoradiation with oral tegafur within a multidisciplinary therapeutic approach in patients with T3-4 rectal cancer. Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1378-84.  

Wang LW, Yang SH, Lin JK, Lin TC, Chan WK, Chen WS, Wang HS, Jiang JK, Lee RC, Li AF, Chao Y, Chi KH, Yen SH. Pre-operative chemoradiotherapy with oral tegafur-uracil and leucovorin for rectal cancer. J Surg Oncol. 2005 Mar 15;89(4):256-63; discussion 263-4 

Chau I, Norman AR, Cunningham D, Tait D, Ross PJ, Iveson T, Hill M, Hickish T, Lofts F, Jodrell D, Webb A, Oates JR. A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol. 2005 Apr;16(4):549-57.  

Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, Hamilton A, Pan D, Schrag D, Schwartz L, Klimstra DS, Fridman D, Kelsen DP, Saltz LB. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol. 2005 Mar 20;23(9):1803-10.  

Delaunoit T, Alberts SR, Sargent DJ, Green E, Goldberg RM, Krook J, Fuchs C, Ramanathan RK, Williamson SK, Morton RF, Findlay BP. Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. Ann Oncol. 2005 Mar;16(3):425-9. 

Maiello E, Gebbia V, Giuliani F, Paoletti G, Gebbia N, Borsellino N, Carteni G, Pezzella G, Manzione L, Romito S, Lopez M, Colucci G. FOLFIRI regimen in advanced colorectal cancer: the experience of the Gruppo Oncologico dell'Italia Meridionale (GOIM). Ann Oncol. 2005 May;16 Suppl 4:iv56-iv60.  

 Makatsoris T, Kalofonos HP, Aravantinos G, Papadimitriou C, Kastritis E, Rigatos SK, Xiros N, Petsas T, Economopoulos T, Sakadamis AK, Fountzilas G. A Phase II Study of Capecitabine Plus Oxaliplatin (XELOX): A New First-Line Option in Metastatic Colorectal Cancer. Int J Gastrointest Cancer. 2005 Apr;35(2):103-110.

Suzuki H, Kanou Y, Ooshima H, Kawase J, Kudou J, Mizuno Y, Matsumoto S. [Trial of outpatient anti-cancer chemotherapy with infusion of 5-FU and cisplatin for advanced gastric and colorectal cancers] Gan To Kagaku Ryoho. 2005 Feb;32(2):189-93. Japanese. 

 Staritz P, Kienle P, Koch M, Benner A, von Knebel Doeberitz M, Rudi J, Weitz J. Detection of disseminated tumour cells as a potential surrogate-marker for monitoring palliative chemotherapy in colorectal cancer patients. J Exp Clin Cancer Res. 2004 Dec;23(4):633-9. 

 Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Randolph Hecht J, Mass R, Perrou B, Nelson B, Novotny WF. Addition of Bevacizumab to Bolus Fluorouracil and Leucovorin in First-Line Metastatic Colorectal Cancer: Results of a Randomized Phase II Trial. J Clin Oncol. 2005 Feb 28;  

Egreteau J, Boucher E, de Guibert S, Jacquelinet C, Meunier B, Boudjema K, Raoul JL. New Drugs for Colorectal Cancer (Irinotecan, Oxaliplatin, Raltitrexed) Meet Expectations in Routine Practice: A Single Center's Experience Before and After Their Introduction. Int J Gastrointest Cancer. 2005 Feb;35(1):69-76. 

Clancy TE, Dixon E, Perlis R, Sutherland FR, Zinner MJ. Hepatic arterial infusion after curative resection of colorectal cancer metastases: a meta-analysis of prospective clinical trials. J Gastrointest Surg. 2005 Feb 1;9(2):198-206.

Baxter NN, Rothenberger DA, Morris AM, Bullard KM. Adjuvant radiation for rectal cancer: do we measure up to the standard of care? An epidemiologic analysis of trends over 25 years in the United States. Dis Colon Rectum. 2005 Jan;48(1):9-15

Baxter NN, Morris AM, Rothenberger DA, Tepper JE. Impact of preoperative radiation for rectal cancer on subsequent lymph node evaluation: a population-based analysis. Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):426-31. 

Turner II, Russell GB, Blackstock AW, Levine EA. Impact of neoadjuvant therapy on postoperative complications in patients undergoing resection for rectal adenocarcinoma. Am Surg. 2004 Dec;70(12):1045-9. 

Wheeler JM, Dodds E, Warren BF, Cunningham C, George BD, Jones AC, Mortensen NJ. Preoperative chemoradiotherapy and total mesorectal excision surgery for locally advanced rectal cancer: correlation with rectal cancer regression grade. Dis Colon Rectum. 2004 Dec;47(12):2025-31. 

Keam SJ, Dunn CJ, Figgitt DP. Oxaliplatin: in operable colorectal cancer. Drugs. 2005;65(1):89-96; discussion 97-8. 

Kemeny N, Garay CA, Gurtler J, Hochster H, Kennedy P, Benson A, Brandt DS, Polikoff J, Wertheim M, Shumaker G, Hallman D, Burger B, Gupta S. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer. J Clin Oncol. 2004 Dec 1;22(23):4753-61.

Conroy T, Gory-Delabaere G, Adenis A, Bosquet L, Bouche O, Louvet C, Mitry E, Becouarn Y, Bosset JF, Ducreux M, Etienne PL, Merrouche Y, Monges G, Rougier P; Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC); Federation Hospitaliere de France (FHF); Federation Nationale de Cancerologie des Centres Hospitaliers Regionaux et Universitaires (FNCCHRU); Federation Francaise de Cancerologie des Centres Hospitaliers Generaux (FFCCHG); Centres Regionaux de Lutte Contre le Cancer (CRLCC); Federation Francaise de Cancerologie Digestive (FFCD); Societe Nationale Francaise de Gastro-Enterologie (SNFGE); Groupe cooperateur multidisciplinaire en oncologie (Gercor). Clinical practice guideline: 2003 update of Standards, Options et Recommendations for first line palliative chemotherapy in patients with metastatic colorectal cancer (summary report) Bull Cancer. 2004 Oct;91(10):759-68. French. 

Feliu J, Vicent JM, Garcia-Giron C, Constela M, Fonseca E, Aparicio J, Lomas M, Anton-Aparicio L, Dorta FJ, Gonzalez-Baron M; Oncopaz Cooperative Group and Associated Hospitals. Phase II study of UFT and oxaliplatin in first-line treatment of advanced colorectal cancer. Br J Cancer. 2004 Nov 15;91(10):1758-62.  

Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R; German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004 Oct 21;351(17):1731-40.  

Grothey A, Goldberg RM. A review of oxaliplatin and its clinical use in colorectal cancer. Expert Opin Pharmacother. 2004 Oct;5(10):2159-70. 

Thirion P, Michiels S, Pignon JP, Buyse M, Braud AC, Carlson RW, O'Connell M, Sargent P, Piedbois P; Meta-Analysis Group in Cancer. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol. 2004 Sep 15;22(18):3766-75. 

Kinoshita H, Watanabe T, Yanagisawa A, Nagawa H, Kato Y, Muto T. Pathological changes of advanced lower-rectal cancer by preoperative radiotherapy. Hepatogastroenterology. 2004 Sep-Oct;51(59):1362-6.

Onate-Ocana LF, Montesdeoca R, Lopez-Graniel CM, Aiello-Crocifoglio V, Mondragon-Sanchez R, Cortina-Borja M, Herrera-Goepfert R, Oros-Ovalle C, Gallardo-Rincon D. Identification of Patients with High-risk Lymph Node-negative Colorectal Cancer and Potential Benefit from Adjuvant Chemotherapy. Jpn J Clin Oncol. 2004 Jun;34(6):323-8. 

Minsky BD. Combined modality therapy of resectable rectal cancer: current approaches. Tech Coloproctol. 2004 Aug;8(2):67-76. 

Smith RE, Colangelo L, Wieand HS, Begovic M, Wolmark N. Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01. J Natl Cancer Inst. 2004 Aug 4;96(15):1128-32. 

Negri F, Musolino A, Cunningham D, Pastorino U, Ladas G, Norman AR. Retrospective study of resection of pulmonary metastases in patients with advanced colorectal cancer: the development of a preoperative chemotherapy strategy. Clin Colorectal Cancer. 2004 Jul;4(2):101-6.  

Martenson JA Jr, Willett CG, Sargent DJ, Mailliard JA, Donohue JH, Gunderson LL, Thomas CR Jr, Fisher B, Benson AB 3rd, Myerson R, Goldberg RM. Phase III study of adjuvant chemotherapy and radiation therapy compared with chemotherapy alone in the surgical adjuvant treatment of colon cancer: results of intergroup protocol 0130. J Clin Oncol. 2004 Aug 15;22(16):3277-83. 

Guillem JG, Moore HG, Akhurst T, Klimstra DS, Ruo L, Mazumdar M, Minsky BD, Saltz L, Wong WD, Larson S. Sequential preoperative fluorodeoxyglucose-positron emission tomography assessment of response to preoperative chemoradiation: a means for determining longterm outcomes of rectal cancer. J Am Coll Surg. 2004 Jul;199(1):1-7.  

Mitry E, Douillard JY, Van Cutsem E, Cunningham D, Magherini E, Mery-Mignard D, Awad L, Rougier P. Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials. Ann Oncol. 2004 Jul;15(7):1013-7.  

Figueredo A, Charette ML, Maroun J, Brouwers MC, Zuraw L. Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group. J Clin Oncol. 2004 Aug 15;22(16):3395-407. Epub 2004 Jun 15. 

Zondor SD, Medina PJ. Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies.
Ann Pharmacother. 2004 Jul-Aug;38(7-8):1258-64.  

Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A; Multicenter International Study of Oxaliplatin/5- luorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004 Jun 3;350(23):2343-51.  

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004 Jun 3;350(23):2335-42.  

Tang R, Wang JY, Fan CW, Tsao KC, Chen HH, Wu CM, Chen JS, Changchien CR, Hsieh LL. p53 is an independent pre-treatment markers for long-term survival in stage II and III colorectal cancers: an analysis of interaction between genetic markers and fluorouracil-based adjuvant therapy. Cancer Lett. 2004 Jul 8;210(1):101-9.  

Cassidy J, Tabernero J, Twelves C, Brunet R, Butts C, Conroy T, Debraud F, Figer A, Grossmann J, Sawada N, Schoffski P, Sobrero A, Van Cutsem E, Diaz-Rubio E. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol. 2004 Jun 1;22(11):2084-91. 

Gal R, Sadikov E, Sulkes J, Klein B, Koren R. Deleted in colorectal cancer protein expression as a possible predictor of response to adjuvant chemotherapy in colorectal cancer patients. Dis Colon Rectum. 2004 Jul;47(7):1216-24

Labianca R, Fossati R, Zaniboni A, Torri V, Marsoni S, Nitti D, Boffi L, Scatizzi M, Tardio B, Mastrodonato N, Banducci S, Consani G, Pancera G; ACOI/GIVIO/GISCAD Investigators. Randomized trial of intraportal and/or systemic adjuvant chemotherapy in patients with colon carcinoma. J Natl Cancer Inst. 2004 May 19;96(10):750-8. 

Gill S, Loprinzi CL, Sargent DJ, Thome SD, Alberts SR, Haller DG, Benedetti J, Francini G, Shepherd LE, Francois Seitz J, Labianca R, Chen W, Cha SS, Heldebrant MP, Goldberg RM. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?
J Clin Oncol. 2004 May 15;22(10):1797-806.  

Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 2004 Apr 1;22(7):1209-14.  

Chau I, Allen MJ, Cunningham D, Norman AR, Brown G, Ford HE, Tebbutt N, Tait D, Hill M, Ross PJ, Oates J. The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer. J Clin Oncol. 2004 Apr 15;22(8):1420-9.

Ammann K, Kirchmayr W, Klaus A, Muhlmann G, Kafka R, Oberwalder M, De Vries A, Ofner D, Weiss H. Impact of neoadjuvant chemoradiation on anal sphincter function in patients with carcinoma of the midrectum and low rectum. Arch Surg. 2003 Mar;138(3):257-61.

Shi W, Teschendorf C, Muzyczka N, Siemann DW. Gene therapy delivery of endostatin enhances the treatment efficacy of radiation. Radiother Oncol. 2003 Jan;66(1):1-9.

Hochster H. The role of pemetrexed in the treatment of colorectal cancer. Semin Oncol. 2002 Dec;29(6 Suppl 18):54-6.

Rothenberg ML. Current status of capecitabine in the treatment of colorectal cancer.
Oncology (Huntingt). 2002 Dec;16(12 Suppl No 14):16-22.

Kerr D. Capecitabine/irinotecan in colorectal cancer: European early-phase data and planned trials.
Oncology (Huntingt). 2002 Dec;16(12 Suppl No 14):12-5.

Ychou M, Raoul JL, Desseigne F, Borel C, Caroli-Bosc FX, Jacob JH, Seitz JF, Kramar A, Hua A, Lefebvre P, Couteau C, Merrouche Y. High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer. Cancer Chemother Pharmacol. 2002 Nov;50(5):383-91.

Barratt PL, Seymour MT, Stenning SP, Georgiades I, Walker C, Birbeck K, Quirke P.
DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study. Lancet. 2002 Nov 2;360(9343):1381-91.

Yamamura T, Yabe K, Oka H, Kouzuma T, Kawahara H, Wakayama T, Sugiura A, Hagiwara M, Ohdate K, Miyajima N, Maeda C, Okamura R, Miyahara T, Moriyama Y, Yamaguchi S, Gunji A.
Final results of a randomized clinical trial of adjuvant intraportal chemotherapy for colorectal cancer: Intraportal Chemotherapy for Colorectal Cancer Group.
Gan To Kagaku Ryoho. 2002 Oct;29(10):1765-71. Japanese.

Dahlberg M, Stenborg A, Pahlman L, Glimelius B.
Cost-effectiveness of preoperative radiotherapy in rectal cancer: results from the Swedish Rectal Cancer Trial.
Int J Radiat Oncol Biol Phys. 2002 Nov 1;54(3):654-60.

Iwashyna TJ, Lamont EB.
Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III colon cancer.
J Clin Oncol. 2002 Oct 1;20(19):3992-8.

te Velde EA, Vogten JM, Gebbink MF, van Gorp JM, Voest EE, Borel Rinkes IH.
Enhanced antitumour efficacy by combining conventional chemotherapy with angiostatin or endostatin in a liver metastasis model.
Br J Surg. 2002 Oct;89(10):1302-9.

Mohiuddin M, Marks G, Marks J. Long-term results of reirradiation for patients with recurrent rectal carcinoma. Cancer. 2002 Sep 1;95(5):1144-50.

Gerard JP, Chapet O, Ramaioli A, Romestaing P. Long-term control of T2-T3 rectal adenocarcinoma with radiotherapy alone. Int J Radiat Oncol Biol Phys. 2002 Sep 1;54(1):142-9.

Delaney CP, Lavery IC, Brenner A, Hammel J, Senagore AJ, Noone RB, Fazio VW. Preoperative radiotherapy improves survival for patients undergoing total mesorectal excision for stage T3 low rectal cancers. Ann Surg. 2002 Aug;236(2):203-7.

Ruo L, Tickoo S, Klimstra DS, Minsky BD, Saltz L, Mazumdar M, Paty PB, Wong WD, Larson SM, Cohen AM, Guillem JG. Long-term prognostic significance of extent of rectal cancer response to preoperative radiation and chemotherapy. Ann Surg. 2002 Jul;236(1):75-81.

Theodoropoulos G, Wise WE, Padmanabhan A, Kerner BA, Taylor CW, Aguilar PS, Khanduja KS. T-level downstaging and complete pathologic response after preoperative chemoradiation for advanced rectal cancer result in decreased recurrence and improved disease-free survival. Dis Colon Rectum. 2002 Jul;45(7):895-903.

Nakagawa WT, Rossi BM, de O Ferreira F, Ferrigno R, David Filho WJ, Nishimoto IN, Vieira RA, Lopes A. Chemoradiation instead of surgery to treat mid and low rectal tumors: is it safe? Ann Surg Oncol. 2002 Jul;9(6):568-73.

Valentini V, Coco C, Picciocchi A, Morganti AG, Trodella L, Ciabattoni A, Cellini F, Barbaro B, Cogliandolo S, Nuzzo G, Doglietto GB, Ambesi-Impiombato F, Cosimelli M. Does downstaging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long-term analysis of 165 patients. Int J Radiat Oncol Biol Phys. 2002 Jul 1;53(3):664-74

Marusch F, Koch A, Schmidt U, Geissler S, Meyer L, Jost J, Ulrich B, Gastinger I, Kockerling F, Lippert H. [Prospective multi-center study colon/rectum carcinoma (primary tumors)--Results of the year 2000] Zentralbl Chir. 2002 Apr;127(4):332-49. German.

Helfritzsch H, Bohm B, Thiele M, Altendorf-Hoffmann A, Scheele J. [Results of the surgical therapy in advanced colorectal cancer] Zentralbl Chir. 2002 Apr;127(4):302-6. German.

Dunne JR, Gannon CJ, Osborn TM, Taylor MD, Malone DL, Napolitano LM. Preoperative anemia in colon cancer: assessment of risk factors. Am Surg. 2002 Jun;68(6):582-7.

Petersen VC, Baxter KJ, Love SB, Shepherd NA. Identification of objective pathological prognostic determinants and models of prognosis in Dukes' B colon cancer. Gut. 2002 Jul;51(1):65-9.

Shibata D, Paty PB, Guillem JG, Wong WD, Cohen AM. Surgical management of isolated retroperitoneal recurrences of colorectal carcinoma. Dis Colon Rectum. 2002 Jun;45(6):795-801.

Wichmann MW, Muller C, Hornung HM, Lau-Werner U, Schildberg FW. Results of Long-term Follow-up after Curative Resection of Dukes A Colorectal Cancer. World J Surg. 2002 Jun;26(6):732-6.

Lobo DN, Bostock KA, Neal KR, Perkins AC, Rowlands BJ, Allison SP. Effect of salt and water balance on recovery of gastrointestinal function after elective colonic resection: a randomised controlled trial. Lancet. 2002 May 25;359(9320):1812-8.

Phang PT, MacFarlane JK, Taylor RH, Cheifetz RE, Davis N, Hay JH, McGregor G, Speers C, Sullivan BJ, Pitts J, Coldman AJ. Effects of positive resection margin and tumor distance from anus on rectal cancer treatment outcomes. Am J Surg. 2002 May;183(5):504-8.

Barton JB, Langdale LA, Cummins JS, Stelzner M, Lynge DC, Mock CN, Nason KS, Billingsley KG. The utility of routine preoperative computed tomography scanning in the management of veterans with colon cancer. Am J Surg. 2002 May;183(5):499-503.

Schell SR, Zlotecki RA, Mendenhall WM, Marsh RW, Vauthey JN, Copeland EM 3rd. Transanal excision of locally advanced rectal cancers downstaged using neoadjuvant chemoradiotherapy. J Am Coll Surg. 2002 May;194(5):584-90; discussion 590-1.

Rinkus KM, Russell GB, Levine EA. Prognostic significance of nodal disease following preoperative radiation for rectal adenocarcinoma. Am Surg. 2002 May;68(5):482-7.

Lujan HJ, Plasencia G, Jacobs M, Viamonte M 3rd, Hartmann RF. Long-term survival after laparoscopic colon resection for cancer: complete five-year follow-up. Dis Colon Rectum. 2002 Apr;45(4):491-501.

Chang GJ, Berry JM, Jay N, Palefsky JM, Welton ML. Surgical treatment of high-grade anal squamous intraepithelial lesions: a prospective study. Dis Colon Rectum. 2002 Apr;45(4):453-8.
 
Massacesi C, Pistilli B, Valeri M, Lippe P, Rocchi MB, Cellerino R, Piga A. Predictors of short-term survival and progression to chemotherapy in patients with advanced colorectal cancer treated with 5-fluorouracil-based regimens. Am J Clin Oncol. 2002 Apr;25(2):140-8.

Magne N, Francois E, Broisin L, Guardiola E, Ramaioli A, Ferrero JM, Namer M. Palliative 5-fluorouracil-based chemotherapy for advanced colorectal cancer in the elderly: results of a 10-year experience. Am J Clin Oncol. 2002 Apr;25(2):126-30.

Fata F, Mirza A, Craig G, Nair S, Law A, Gallagher J, Ellison N, Bernath A. Efficacy and toxicity of adjuvant chemotherapy in elderly patients with colon carcinoma: a 10-year experience of the Geisinger Medical Center. Cancer. 2002 Apr 1;94(7):1931-8. Review.

Basha G, Landuyt W, Fowler J, Vordermark D, Haustermans K, Geboes K, Van den Bogaert W, Yap SH, Lambin P, Penninckx F. An experimental evaluation of three preoperative radiation regimens for resectable rectal cancer. Ann Surg Oncol. 2002 Apr;9(3):292-7.

Massacesi C, Pistilli B, Valeri M, Lippe P, Rocchi MB, Cellerino R, Piga A. Predictors of short-term survival and progression to chemotherapy in patients with advanced colorectal cancer treated with 5-fluorouracil-based regimens. Am J Clin Oncol. 2002 Apr;25(2):140-8.

Magne N, Francois E, Broisin L, Guardiola E, Ramaioli A, Ferrero JM, Namer M. Palliative 5-fluorouracil-based chemotherapy for advanced colorectal cancer in the elderly: results of a 10-year experience. Am J Clin Oncol. 2002 Apr;25(2):126-30.

Fata F, Mirza A, Craig G, Nair S, Law A, Gallagher J, Ellison N, Bernath A. Efficacy and toxicity of adjuvant chemotherapy in elderly patients with colon carcinoma: a 10-year experience of the Geisinger Medical Center. Cancer. 2002 Apr 1;94(7):1931-8. Review.

Kandioler D, Zwrtek R, Ludwig C, Janschek E, Ploner M, Hofbauer F, Kuhrer I, Kappel S, Wrba F, Horvath M, Karner J, Renner K, Bergmann M, Karner-Hanusch J, Potter R, Jakesz R, Teleky B, Herbst F. TP53 genotype but not p53 immunohistochemical result predicts response to preoperative short-term radiotherapy in rectal cancer. Ann Surg. 2002 Apr;235(4):493-8.

Lee JH, Lee JH, Ahn JH, Bahng H, Kim TW, Kang YK, Lee KH, Kim JC, Yu CS, Kim JH, Ahn SD, Kim WK, Kim SH, Lee JS.Randomized trial of postoperative adjuvant therapy in stage II and III rectal cancer to define the optimal sequence of chemotherapy and radiotherapy: a preliminary report. J Clin Oncol. 2002 Apr 1;20(7):1751-8.

Tepper JE, O'Connell M, Niedzwiecki D, Hollis DR, Benson AB 3rd, Cummings B, Gunderson LL, Macdonald JS, Martenson JA, Mayer RJ. Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control--final report of intergroup 0114. J Clin Oncol. 2002 Apr 1;20(7):1744-50.

Edler D, Glimelius B, Hallstrom M, Jakobsen A, Johnston PG, Magnusson I, Ragnhammar P, Blomgren H. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy.J Clin Oncol. 2002 Apr 1;20(7):1721-8.

Kato T, Ohashi Y, Nakazato H, Koike A, Saji S, Suzuki H, Takagi H, Nimura Y, Hasumi A, Baba S, Manabe T, Maruta M, Miura K, Yamaguchi A. Efficacy of oral UFT as adjuvant chemotherapy to curative resection of colorectal cancer: multicenter prospective randomized trial.
Langenbecks Arch Surg. 2002 Mar;386(8):575-81.

Kohne CH, Cunningham D, Di CF, Glimelius B, Blijham G, Aranda E, Scheithauer W, Rougier P, Palmer M, Wils J, Baron B, Pignatti F, Schoffski P, Micheel S, Hecker H. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients.
Ann Oncol. 2002 Feb;13(2):308-17.

Herold C, Ocker M, Ganslmayer M, Gerauer H, Hahn EG, Schuppan D. Ciprofloxacin induces apoptosis and inhibits proliferation of human colorectal carcinoma cells. Br J Cancer. 2002 Feb 1;86(3):443-8.

Punt CJ, Blanke CD, Zhang J, Hammershaimb L. Integrated analysis of overall survival in two randomised studies comparing 5-fluorouracil/leucovorin with or without trimetrexate in advanced colorectal cancer. Ann Oncol. 2002 Jan;13(1):92-4.

Stack E, DuBois RN. Role of cyclooxygenase inhibitors for the prevention of colorectal cancer. Gastroenterol Clin North Am. 2001 Dec;30(4):1001-10.

Calvo FA, Gomez-Espi M, Diaz-Gonzalez JA, Cantalapiedra R, Marcos P, Alvarado A, Garcia Alfonso P, Herranz R, Alvarez E. Pathologic downstaging of T3-4Nx rectal cancer after chemoradiation: 5-fluorouracil vs. Tegafur.

Chau I, Webb A, Cunningham D, Hill M, Waters JS, Norman A, Massey A. Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer. Br J Cancer. 2001 Nov 2;85(9):1258-64.

Bouchardy C, Queneau PE, Fioretta G, Usel M, Zellweger M, Neyroud I, Raymond L, de Wolf C, Sappino AP. Adjuvant chemotherapy for colon carcinoma with positive lymph nodes: use and benefit in routine health care practice.
Br J Cancer. 2001 Nov 2;85(9):1251-7.

Lorchel F, Bosset JF, Bartholomot B, Baron MH, Mantion G, Pelissier EP, Goubard O, Maingon P. [Clinical target volume for preoperative radiotherapy of rectal cancers] Cancer Radiother. 2001 Oct;5(5):542-9. Review. French.

Khan ZA, Jonas SK, Feldmann KA, Patel H, Wharton RQ, Tarragona A, Ivison A, Allen-Mersh TG. P53 mutation and response to hepatic arterial floxuridine in patients with colorectal liver metastases. J Cancer Res Clin Oncol. 2001 Nov;127(11):675-80.

[No authors listed] Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials. Lancet. 2001 Oct 20;358(9290):1291-304.

Sargent DJ, Goldberg RM, Jacobson SD, Macdonald JS, Labianca R, Haller DG, Shepherd LE, Seitz JF, Francini G. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med. 2001 Oct 11;345(15):1091-7.

Myerson RJ, Kong F, Birnbaum EH, Fleshman JW, Kodner IJ, Picus J, Ratkin GA, Read TE, Walz BJ. Radiation therapy for epidermoid carcinoma of the anal canal, clinical and treatment factors associated with outcome. Radiother Oncol. 2001 Oct;61(1):15-22.

Sarela AI, Guthrie JA, Seymour MT, Ride E, Guillou PJ, O'Riordain DS. Non-operative management of the primary tumour in patients with incurable stage IV colorectal cancer. Br J Surg. 2001 Oct;88(10):1352-6.

Aumock A, Birnbaum EH, Fleshman JW, Fry RD, Gambacorta MA, Kodner IJ, Malyapa RS, Read TE, Walz BJ, Myerson RJ. Treatment of rectal adenocarcinoma with endocavitary and external beam radiotherapy: results for 199 patients with localized tumors. Int J Radiat Oncol Biol Phys. 2001 Oct 1;51(2):363-70.

Jones R, Twelves C. Oral uracil-tegafur: an alternative to intravenous 5-fluorouracil? Expert Opin Pharmacother. 2001 Sep;2(9):1495-505.

Sarela AI, Guthrie JA, Seymour MT, Ride E, Guillou PJ, O'Riordain DS. Non-operative management of the primary tumour in patients with incurable stage IV colorectal cancer Br J Surg. 2001 Oct;88(10):1352-6.

Martling A, Holm T, Johansson H, Rutqvist LE, Cedermark B. The Stockholm II trial on preoperative radiotherapy in rectal carcinoma: long-term follow-up of a population-based study. Cancer. 2001 Aug 15;92(4):896-902.

Tjandra JJ, Reading DM, McLachlan SA, Gunn IF, Green MD, McLaughlin SJ, Millar JL, Pedersen JS. Phase II clinical trial of preoperative combined chemoradiation for T3 and T4 resectable rectal cancer: preliminary results. Dis Colon Rectum. 2001 Aug;44(8):1113-22.

Schrag D, Gelfand SE, Bach PB, Guillem J, Minsky BD, Begg CB. Who gets adjuvant treatment for stage II and III rectal cancer? Insight from surveillance, epidemiology, and end results--Medicare. J Clin Oncol. 2001 Sep 1;19(17):3712-8.

Myerson RJ, Valentini V, Birnbaum EH, Cellini N, Coco C, Fleshman JW, Gambacorta MA, Genovesi D, Kodner IJ, Picus J, Ratkin GA, Read TE. A phase I/II trial of three-dimensionally planned concurrent boost radiotherapy and protracted venous infusion of 5-FU chemotherapy for locally advanced rectal carcinoma. Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1299-308.

Dempke W, Rie C, Grothey A, Schmoll HJ Cyclooxygenase-2: a novel target for cancer chemotherapy? J Cancer Res Clin Oncol. 2001 Jul;127(7):411-7. Review.

Ann Surg Oncol 2000 Aug;7(7):490-5 Surgery after downstaging of unresectable hepatic tumors with intra-arterialchemotherapy. Meric F, Patt YZ, Curley SA, Chase J, Roh MS, Vauthey JN, Ellis LM

Aust N Z J Surg 2000 Aug;70(8):553-9 Rectal cancer: changing patterns of referral for radiation therapy 1982-1997. Stevens G, Firth I, Solomon M, Saw R, Glenn D, Eyers A, West R

JAMA 2000 Aug 23-30;284(8):1008-15 Preoperative radiotherapy for resectable rectal cancer: A meta-analysis. Camma C, Giunta M, Fiorica F, Pagliaro L, Craxi A, Cottone M

Vopr Onkol 1999;45(1):35-7 Results of combined treatment of patients with rectal cancer using a singlepreoperative radiotherapy dose of 7.5 Gy. [Article in Russian] Kharchenko VP, Pan'shin GA, Izvekova OV, Firsov EF, Galil-Ogly GA, Shumarova LK

Br J Surg 2000 Aug;87(8):1006-15 Hyperthermic intraperitoneal chemoperfusion in the treatment of locally advancedintra-abdominal cancer. Ceelen WP, Hesse U, de Hemptinne B, Pattyn P

Int J Radiat Oncol Biol Phys 2000 Aug 1;48(1):219-26 High-dose-rate intraoperative brachytherapy for recurrent colorectal cancer. Alektiar KM, Zelefsky MJ, Paty PB, Guillem J, Saltz LB, Cohen AM, Minsky BD

Chung Hua Chung Liu Tsa Chih 1998 May;20(3):222-4 Early postoperative intraperitoneal perfusion chemotherapy for advancedcolorectal cancer [Article in Chinese]Sun N, Cai Z, Zhang C

Australas Radiol 1999 May;43(2):215-9 Pre-operative chemo-radiotherapy in locally advanced rectal cancer: is this the way of future management? Elsaleh H, Joseph D, Levitt M, Dewar J, Van Hazel G, Einhorn S, Cameron F, Osborne M, Latham M, Robbins P

Harefuah 2000 Jan 16;138(2):96-9, 175 Brief preoperative radiotherapy reduces local recurrences and improves survivalin rectal cancer. [Article in Hebrew]Peretz T, Weshler Z, Goldberg Y, Durst AL, Freund HR

J Surg Oncol 2000 May;74(1):41-4 Treatment of peritoneal carcinomatosis with intent to cure.Cavaliere F, Perri P, Di Filippo F, Giannarelli D, Botti C, Cosimelli M, TedescoM, Principi F, Laurenzi L, Cavaliere R

Int J Radiat Oncol Biol Phys 2000 Jun 1;47(3):725-33 Phase II trial of adjuvant radiation and intraperitoneal 5-fluorouracil forlocally advanced colon cancer: results with 10-year follow-up. Palermo JA, Richards F, Lohman KK, Lovelace JV, Atkinson J, Case LD, White DR, Blackstock AW

Int J Radiat Oncol Biol Phys 2000 Jun 1;47(3):719-24 A pilot study of preoperative continuous infusion 5-fluorouracil, externalmicrowave hyperthermia, and external beam radiotherapy for treatment of locallyadvanced, unresectable, or recurrent rectal cancer. Anscher MS, Lee C, Hurwitz H, Tyler D, Prosnitz LR, Jowell P, Rosner G, Samulski T, Dewhirst MW

Int J Radiat Oncol Biol Phys 2000 Jun 1;47(3):713-8 Prospective trial of preoperative concomitant boost radiotherapy with continuous infusion 5-fluorouracil for locally advanced rectal cancer. Janjan NA, Crane CN, Feig BW, Cleary K, Dubrow R, Curley SA, Ellis LM, Vauthey J, Lenzi R, Lynch P, Wolff R, Brown T, Pazdur R, Abbruzzese J, Hoff PM, Allen P, Brown B, Skibber J

Anticancer Drugs 2000 Mar;11(3):155-63 Preoperative UFT administration for patients with advanced colorectalcancer--increased uptake of 5-fluorouracil by tumor tissue is a prognosticfactor.Nakagoe T, Ishikawa H, Sawai T, Tsuji T, Ayabe H, Eida K, Nogawa T, Nakamura Y, Kunisaki T, Tobinaga K, Furukawa M, Ino M

Strahlenther Onkol 2000 Apr;176(4):161-7 Preoperative radiation with concurrent 5-fluorouracil for locally advancedT4-primary rectal cancer. Rodel C, Grabenbauer GG, Schick C, Papadopoulos T, Hohenberger W, Sauer R

Anticancer Res 2000 Mar-Apr;20(2B):1069-75 Multicenter randomized prospective study of adjuvant chemotherapy with UFT andmitomycin C in advanced colorectal cancer. Nakagoe T, Ishikawa H, Sawai T, Tuji T, Ayabe H, Eida K, Nogawa T, Nakamura Y, Kunisaki T, Tobinaga K, Furukawa M, Ino M

Int J Radiat Oncol Biol Phys 2000 May 1;47(2):425-33 Feasibility and first results of multimodality treatment, combining EBRT, extensive surgery, and IOERT in locally advanced primary rectal cancer.Mannaerts GH, Martijn H, Crommelin MA, Dries W, Repelaer van Driel OJ, Rutten HJ

Ann Surg 2000 Apr;231(4):449-56 Adjuvant intraperitoneal 5-fluorouracil in high-risk colon cancer: A multicenterphase III trial.Vaillant JC, Nordlinger B, Deuffic S, Arnaud JP, Pelissier E, Favre JP, Jaeck D, Fourtanier G, Grandjean JP, Marre P, Letoublon C

Strahlenther Onkol 2000 Mar;176(3):112-7 The postoperative adjuvant radiation therapy and radiochemotherapy for UICC stage II and III rectal cancer. A retrospective analysis. Bagatzounis A, Willner J, Oppitz U, Flentje M

Cancer 2000 Mar 1;88(5):1007-15 Preoperative treatment with tegafur suppositories enhances apoptosis and reduces the intratumoral microvessel density of human colorectal carcinoma. Matsuura T, Fukuda Y, Fujitaka T, Nishisaka T, Sakatani T, Ito H

J Natl Cancer Inst 2000 Mar 1;92(5):388-96 Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02. Wolmark N, Wieand HS, Hyams DM, Colangelo L, Dimitrov NV, Romond EH, Wexler M, Prager D, Cruz AB Jr, Gordon PH, Petrelli NJ, Deutsch M, Mamounas E, Wickerham DL, Fisher ER, Rockette H, Fisher B N. Wolmark, D. L.Wickerham, E. R. Fisher, B. Fisher, National Surgical Adjuvant

Anticancer Res 1999 Nov-Dec;19(6C):5529-34 Selective use of preoperative radiotherapy in the treatment of cancer in the lower two thirds of the rectum. Ketel JM, Verschueren RC, Mulder NH, Szabo BG, Karrenbeld A

Ann Surg Oncol 2000 Jan-Feb;7(1):38-44 Preoperative combined radiotherapy and chemotherapy for middle and lower rectalcancer: preliminary results. Pucciarelli S, Friso ML, Toppan P, Fornasiero A, Carnio S, Marchiori E, Lise M

Ann Chir 1999;53(10):1003-10 Preoperative radiotherapy of rectal cancer. The Lyons experience, 1985-1996. Prognostic study apropos of 312 patients [Article in French] Gerard JP, Chapet O, Morignat E, Romestaing P, Mornex F, Acharki A

Arch Surg 2000 Feb;135(2):182-5 Stage III colon cancers: why adjuvant chemotherapy is not offered to elderlypatients. Mahoney T, Kuo YH, Topilow A, Davis JM

Int J Radiat Oncol Biol Phys 2000 Jan 15;46(2):323-7 Preoperative radiochemotherapy in rectal cancer: long-term results of a phase IItrial. Bosset JF, Magnin V, Maingon P, Mantion G, Pelissier EP, Mercier M, Chaillard G, Horiot JC

Radiother Oncol 1999 Dec;53(3):177-87 Late complications after a combined pre and postoperative (sandwich)radiotherapy for rectal cancer. Svoboda V, Beck-Bornholdt HP, Herrmann T, Alberti W, Jung H

Br J Surg 2000 Jan;87(1):97-9 Prospective audit following the introduction of short-course preoperativeradiotherapy for rectal cancer. Lele S, Radstone D, Eremin J, Kendal R, Hosie KB

Clin Oncol (R Coll Radiol) 1999;11(5):334-9 A pilot study of continuous, hyperfractionated, accelerated radiotherapy inrectal adenocarcinoma. Glynne-Jones R, Saunders MI, Hoskin P, Phillips H

Surg Today 1999;29(10):992-8 Improved outcome following preoperative radiochemotherapy: 40.5 Gy accelerated hyperfractionation and 5-fluorouracil suppositories for patients with carcinoma of the lower rectum. Horie H, Kashiwagi H, Konishi F, Furuta K, Ozawa A, Kanazawa K

Hepatogastroenterology 1999 Sep-Oct;46(29):2825-30 Pre-operative radiotherapy in rectal cancer: evaluation of irradiation effects on cellular undifferentiation and its influence on prognosis. Reis Neto JA, Quilici FA, Cordeiro F, Ciquini S, Reis JA Jr

Ann Ital Chir 1999 Jul-Aug;70(4):551-7; discussion 558 The integrated radiosurgical treatment of rectal cancer [Article in Italian]Lo Schiavo F, Iovino F, Lojodice F, Cimmino F, Docimo G

Cancer 1999 Nov 15;86(10):1952-8 Outcomes of patients receiving radiation for carcinoma of the rectum. Results of the 1988-1989 patterns of care study. Coia LR, Gunderson LL, Haller D, Hoffman J, Mohiuddin M, Tepper JE, Berkey B, Owen JB, Hanks GE

J Clin Oncol 1999 Aug;17(8):2396 Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. Francois Y, Nemoz CJ, Baulieux J, Vignal J, Grandjean JP, Partensky C, Souquet JC, Adeleine P, Gerard JP

Dis Colon Rectum 1999 Oct;42(10):1276-83; discussion 1283-4 Preoperative combined radiotherapy and chemotherapy for rectal cancer does not affect early postoperative morbidity and mortality in low anterior resection. Pucciarelli S, Toppan P, Friso ML, Fornasiero A, Vieceli G, Marchiori E, Lise M

Aust N Z J Surg 1999 Oct;69(10):737-42 Pre-operative chemoradiotherapy in locally advanced rectal cancer. Elsaleh H, Joseph D, Levitt M, House A, Robbins P

Aust N Z J Surg 1999 Oct;69(10):729-32 Peritonectomy and intraperitoneal chemotherapy in appendiceal and colorectal cancer. Horsell KW, Merten S, Clingan P, King DW, Morris DL

Ned Tijdschr Geneeskd 1999 Sep 11;143(37):1863-8 Hyperthermic intra-peritoneal chemotherapy (HIPEC) in patients with peritoneal pseudomyxoma or peritoneal metastases of colorectal carcinoma; good preliminary results from the Netherlands Cancer Institute. [Article in Dutch] Zoetmulder FA, van der Vange N, Witkamp AJ, Kaag MM, Boot H, Beijnen JH

Oncol Rep 1999 Nov-Dec;6(6):1421-4 Retrospective evaluation of toxicity in three different schedules of adjuvant chemotherapy for patients with resected colorectal cancer. TTD Spanish Cooperative Group. Sastre J, Navarro M, Aranda E, Fonseca E, Checa T, Alonso MC, Gallen M, Camps C, Anton A, Diaz-Rubio E

Semin Surg Oncol 1999 Oct-Nov;17(3):199-205 The influence of pre-operative radiation therapy on the patterns of recurrence in rectal adenocarcinoma. Luna-Perez P, Rodriguez-Ramirez S, Gonzalez-Macouzet J, Rodriguez-Coria DF, Delgado S, Lopez MJ

Gan To Kagaku Ryoho 1999 Aug;26(9):1289-93 Comparative study of histopathological effects of preoperative chemotherapy using UFT and in vitro MTT assay of colonoscopy specimens from patients with colorectal cancer. [Article in Japanese] Imai S, Mochizuki F, Fujii M

Langenbecks Arch Surg 1999 Aug;384(4):328-38 Relevance of neoadjuvant and adjuvant treatment for patients with resectable liver metastases of colorectal carcinoma. Lorenz M, Muller HH, Staib-Sebler E, Vetter G, Gog C, Petrowsky H, Kohne CH

Anticancer Res 1999 May-Jun;19(3B):2317-21 Peritonectomy combined with intraperitoneal chemohyperthermia in abdominal cancer with peritoneal carcinomatosis: phase I-II study. Gilly FN, Beaujard A, Glehen O, Grandclement E, Caillot JL, Francois Y, Sadeghi-Looyeh B, Gueugniaud PY, Garbit F, Benoit M, Bienvenu J, Vignal J

Dis Colon Rectum 1999 Aug;42(8):1065-9; discussion 1069-71 Influence of erythropoietin on transfusion requirements in patients receiving preoperative chemoradiotherapy for rectal cancer. Levine EA, Laborde C, Hambrick E, McKnight CA, Vijayakumar S

Cancer J Sci Am 1999 Jul-Aug;5(4):242-7 Does postoperative irradiation play a role in the adjuvant therapy of stage T4 colon cancer? Willett CG, Goldberg S, Shellito PC, Grossbard M, Clark J, Fung C, Proulx G, Daly M, Kaufman DS

Cancer 1999 Aug 1;86(3):398-404 Preoperative radiation therapy for patients with T2-T3 carcinoma of themiddle-to-lower rectum.Bozzetti F, Baratti D, Andreola S, Zucali R, Schiavo M, Spinelli P, Gronchi A, Bertario L, Mariani L, Gennari L

Int J Radiat Oncol Biol Phys 1999 Jul 15;44(5):1027-38 Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: the M. D. Anderson Cancer Center experience. Janjan NA, Khoo VS, Abbruzzese J, Pazdur R, Dubrow R, Cleary KR, Allen PK, Lynch PM, Glober G, Wolff R, Rich TA, Skibber J

Int Surg 1999 Jan-Mar;84(1):60-6 Chemohyperthermic peritoneal perfusion for peritoneal dissemination in variousintra-abdominal malignancies.Fujimura T, Yonemura Y, Fujita H, Michiwa Y, Kawamura T, Nojima N, Sato T,Fushida S, Nishimura G, Miwa K, Miyazaki I, Murakami K, Katayama K, Yamaguchi A

Dis Colon Rectum 1999 Jul;42(7):886-93; discussion 893-5 Intraoperative irradiation after surgery for locally recurrent rectal cancer. Hashiguchi Y, Sekine T, Sakamoto H, Tanaka Y, Kazumoto T, Kato S, Sakura M, FuseY, Suda Y

Dis Colon Rectum 1999 Jun;42(6):727-33; discussion 733-5 Selection criteria for treatment of rectal cancer with combined external and endocavitary radiation. Birnbaum EH, Ogunbiyi OA, Gagliardi G, Fry RD, Myerson RJ, Kodner IJ, Fleshman JW

J Clin Oncol 1999 May;17(5):1349-55 Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versusDukes' C colon cancer: results from four National Surgical Adjuvant Breast andBowel Project adjuvant studies (C-01, C-02, C-03, and C-04). Mamounas E, Wieand S, Wolmark N, Bear HD, Atkins JN, Song K, Jones J, Rockette H

Dis Colon Rectum 1999 Feb;42(2):167-73 Prognostic factors in stage T3N0 rectal cancer: do all patients requirepostoperative pelvic irradiation and chemotherapy? Willett CG, Badizadegan K, Ancukiewicz M, Shellito PC

Ann Surg 1999 Apr;229(4):493-7 Improved survival and reduction in local failure rates after preoperativeradiotherapy: evidence for the generalizability of the results of Swedish Rectal Cancer Trial. Dahlberg M, Glimelius B, Pahlman L

Int J Radiat Oncol Biol Phys 1999 Feb 1;43(3):537-43 Five fractions of preoperative radiotherapy for selected cases of rectalcarcinoma: long-term tumor control and tolerance to treatment. Myerson RJ, Genovesi D, Lockett MA, Birnbaum E, Fleshman J, Fry R, Kodner I, Menteer J, Picus J, Read T, Walz B

Int J Radiat Oncol Biol Phys 1999 Feb 1;43(3):531-6 Results of external beam radiotherapy alone for incompletely resected carcinoma of rectosigmoid or rectum: Peter MacCallum Cancer Institute experience 1981-1990. Guiney MJ, Smith JG, Worotniuk V, Ngan S

Rays 1998 Jul-Sep;23(3):580-5 Radiotherapy and local control in rectal cancer. Valentini V, Rosetto ME, Fares C, Mantini G, Salvi G, Turriziani A

Langenbecks Arch Surg 1998 Dec;383(6):416-26 Adjuvant radiochemotherapy--what is the patients benefit? Link KH, Staib L, Schatz M, Suhr P, Rottinger E, Beger HG

Ann Acad Med Singapore 1998 Sep;27(5):733-7 Adjuvant chemotherapy for patients with resected Dukes' C and high-risk B2 colon cancer with fluorouracil and levamisole. Au E, Ang PT, Seow-Choen F, Soo KC, Low CH, Chng HC, Ng BK

Dig Surg 1998;15(4):337-41 Anticancer effects of preoperative chemotherapy on colorectal carcinoma. Kumagai K, Shimizu K, Masuo K, Yamagata K, Tanaka T

World J Surg 1999 Jan;23(1):23-9 Second-look surgery after cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer: analysis of prognostic features. Portilla AG, Sugarbaker PH, Chang D

Strahlenther Onkol 1998 Nov;174(11):556-65 Phase II study on preoperative radio-chemo-thermotherapy in locally advanced rectal carcinoma. [Article in German] Rau B, Wust P, Gellermann J, Tilly W, Hunerbein M, Loffel J, Stahl H, Riess H, Budach V, Felix R, Schlag P

Strahlenther Onkol. 1998 Oct;174(10):497-504.Adjuvant and neoadjuvant therapy of rectal carcinoma. The current status.[Article in German]Rodel C, Hohenberger W, Sauer R

Int J Radiat Oncol Biol Phys 1998 Sep 1;42(2):319-24 Preoperative radiation with concurrent 5-fluorouracil continuous infusion for locally advanced unresectable rectal cancer. Videtic GM, Fisher BJ, Perera FE, Bauman GS, Kocha WI, Taylor M, Vincent MD, Plewes EA, Engel CJ, Stitt LW

Nippon Igaku Hoshasen Gakkai Zasshi 1998 Aug;58(9):503-8 Results of preoperative high-dose-rate intraluminal brachytherapy for resectable rectal cancer. [Article in Japanese] Kamikonya N, Izumi M, Tusboi K, Nogi K, Miyamoto Y, Nakao N

Oncology 1998 Nov-Dec;55(6):521-4 Endoluminal radiotherapy for rectal tumors. Tanum G, Wiig J, Andersen OK

Cancer Prev Control 1997 Oct;1(4):304-19Published erratum appears in Cancer Prev Control 1997 Dec;1(5):351 Adjuvant therapy for stage III colon cancer after complete resection. ProvincialGastrointestinal Disease Site Group. Figueredo A, Fine S, Maroun J, Walker-Dilks C, Wong S

Dis Colon Rectum 1998 Sep;41(9):1087-96 Low rectal cancer: impact of radiation and chemotherapy on surgical treatment. Habr-Gama A, de Souza PM, Ribeiro U Jr, Nadalin W, Gansl R, Sousa AH Jr, Campos FG, Gama-Rodrigues J

Cancer Radiother 1998 May-Jun;2(3):260-5 Preoperative concurrent radiochemotherapy for cancer of the rectum. [Article in French] Berger C, Kirscher S, Felix-Faure C, Chauvet B, Vincent P, Brewer Y, Reboul F

Int J Radiat Oncol Biol Phys 1998 Aug 1;42(1):43-50 Phase I dose escalating trial of hyperfractionated pre-operative chemoradiation for locally advanced rectal cancer. Movsas B, Hanlon AL, Lanciano R, Scher RM, Weiner LM, Sigurdson ER, Hoffman JP, Eisenberg BL, Cooper HS, Provins S, Coia LR

Chirurg 1998 Jul;69(7):759-65 Brief preoperative radiotherapy in surgical therapy of rectal carcinoma. Long-term results of a prospective randomized study. [Article in German] Petersen S, Hellmich G, Baumann M, Herrmann T, Henke G, Ludwig K

Lancet 1998 Jun 6;351(9117):1677-81 Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: a randomised trial. European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group, the Gruppo Interdisciplinare Valutazione Interventi in Oncologia, and the Japanese Foundation for Cancer Research. Rougier P, Sahmoud T, Nitti D, Curran D, Doci R, De Waele B, Nakajima T, Rauschecker H, Labianca R, Pector JC, Marsoni S, Apolone G, Lasser P, Couvreur ML, Wils J

J Am Coll Surg 1998 Aug;187(2):164-70 Combined preoperative radiation and mitomycin/5-fluorouracil treatment for locally advanced rectal adenocarcinoma. Burke SJ, Percarpio BA, Knight DC, Kwasnik EM

Orv Hetil 1998 Jun 28;139(26):1571-5 Low-dose leucovorin and interferon-alpha as modulators of 5-fluorouracil for adjuvant chemotherapy of colorectal cancer. [Article in Hungarian] Pajkos G, Bodoky G, Padi E, Izso J, Szanto J

Recent Results Cancer Res 1998;146:152-60 Intraoperative radiotherapy as adjuvant treatment for stage II/III rectal carcinoma. Eble MJ, Lehnert T, Herfarth C, Wannenmacher M

J Clin Oncol 1998 Jul;16(7):2542-7 Radiation therapy for rectosigmoid and rectal cancer: results of the 1992-1994Patterns of Care process survey.Minsky BD, Coia L, Haller DG, Hoffman J, John M, Landry J, Pisansky TM, WillettC, Mahon I, Owen J, Berkey B, Katz A, Hanks G